Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer - PubMed (original) (raw)
Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer
Paula Maguire et al. Breast Cancer Res Treat. 2005 Nov.
Abstract
Estrogen is involved in both normal mammary development and in breast carcinogenesis. A family history of disease and exposure to estrogen are major risk factors for developing breast cancer. Estrogen exerts its biological effects through binding to the estrogen receptors, estrogen receptor alpha (ESR1) and the more recently discovered estrogen receptor beta (ESR2). Genetic variation in genes involved in estrogen biosynthesis, metabolism and signal transduction have been suggested to play a role in breast cancer risk. We therefore tested the hypothesis that common genetic variants of the ESR2 gene may be associated with increased risk for breast cancer and this risk may vary between breast cancer groups. We investigated three common ESR2 polymorphisms, rs1256049 (G1082A), rs4986938 (G1730A) and rs928554 (Cx+56 A-->G) for association to breast cancer risk. A total of 723 breast cancer cases and 480 controls were included in the study. Of the breast cancer cases, 323 were sporadic and 400 were familial, the familial cases were further divided into familial high-risk and familial low-risk breast cancer cases. We found no overall statistically significant association for any of the single polymorphisms studied. Haplotype analysis suggested one haplotype associated with increased risk in sporadic breast cancer patients (OR = 3.0, p = 0.03). Further analysis is needed to elucidate the role of estrogen receptor beta in breast cancer susceptibility.
Similar articles
- Unique ESR1 and ESR2 estrogen receptor gene variants associated with altered risk of triple-negative breast cancer: A case-control study.
Sghaier I, Zidi S, El-Ghali RM, Daldoul A, Aimagambetova G, Almawi WY. Sghaier I, et al. Gene. 2023 Jan 30;851:146969. doi: 10.1016/j.gene.2022.146969. Epub 2022 Oct 17. Gene. 2023. PMID: 36261089 - Differential association of ESR1 and ESR2 gene variants with the risk of breast cancer and associated features: A case-control study.
Ghali RM, Al-Mutawa MA, Al-Ansari AK, Zaied S, Bhiri H, Mahjoub T, Almawi WY. Ghali RM, et al. Gene. 2018 Apr 20;651:194-199. doi: 10.1016/j.gene.2018.02.011. Epub 2018 Feb 4. Gene. 2018. PMID: 29414691 - A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk.
Yu KD, Rao NY, Chen AX, Fan L, Yang C, Shao ZM. Yu KD, et al. Breast Cancer Res Treat. 2011 Feb;126(1):37-45. doi: 10.1007/s10549-010-0891-2. Breast Cancer Res Treat. 2011. PMID: 20390341 - The Association Between Genetic Polymorphisms in Estrogen Receptor Genes and the Risk of Ocular Disease: A Meta-Analysis.
Ulhaq ZS. Ulhaq ZS. Turk J Ophthalmol. 2020 Aug 26;50(4):216-220. doi: 10.4274/tjo.galenos.2020.91298. Turk J Ophthalmol. 2020. PMID: 32854465 Free PMC article. Review. - The Effects of Sex Protein Receptors and Sex Steroid Hormone Gene Polymorphisms on Breast Cancer Risk.
Jahandoost S, Farhanghian P, Abbasi S. Jahandoost S, et al. J Natl Med Assoc. 2017 Summer;109(2):126-138. doi: 10.1016/j.jnma.2017.02.003. Epub 2017 Mar 1. J Natl Med Assoc. 2017. PMID: 28599754 Review.
Cited by
- Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach.
Islam S, Amin MA, Rengasamy KRR, Mohiuddin AKM, Mahmud S. Islam S, et al. Cancer Med. 2024 Aug;13(15):e70074. doi: 10.1002/cam4.70074. Cancer Med. 2024. PMID: 39101505 Free PMC article. - A deep learning model predicts the presence of diverse cancer types using circulating tumor cells.
Albaradei S, Alganmi N, Albaradie A, Alharbi E, Motwalli O, Thafar MA, Gojobori T, Essack M, Gao X. Albaradei S, et al. Sci Rep. 2023 Nov 30;13(1):21114. doi: 10.1038/s41598-023-47805-2. Sci Rep. 2023. PMID: 38036622 Free PMC article. - Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future.
Yao J, Tao Y, Hu Z, Li J, Xue Z, Zhang Y, Lei Y. Yao J, et al. Front Pharmacol. 2023 Sep 21;14:1225951. doi: 10.3389/fphar.2023.1225951. eCollection 2023. Front Pharmacol. 2023. PMID: 37808197 Free PMC article. Review. - ESR2 polymorphisms on prostate cancer risk: A systematic review and meta-analysis.
Chang X, Wang H, Yang Z, Wang Y, Li J, Han Z. Chang X, et al. Medicine (Baltimore). 2023 Jun 9;102(23):e33937. doi: 10.1097/MD.0000000000033937. Medicine (Baltimore). 2023. PMID: 37335680 Free PMC article. - ESR2 gene variants (rs1256049, rs4986938, and rs1256030) and their association with breast cancer risk.
Gallegos-Arreola MP, Zúñiga-González GM, Figuera LE, Puebla-Pérez AM, Márquez-Rosales MG, Gómez-Meda BC, Rosales-Reynoso MA. Gallegos-Arreola MP, et al. PeerJ. 2022 May 10;10:e13379. doi: 10.7717/peerj.13379. eCollection 2022. PeerJ. 2022. PMID: 35573183 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous